Ebiratide

Summary

Ebiratide (HOE‑427) is a synthetic ACTH(4‑9) peptide analogue belonging to the melanocortin/ACTH family. It is biologically active in the central nervous system but lacks endocrine activity. Research has examined its ability to modulate arousal, sleep architecture, and subjective fatigue, as well as its capacity to cross the blood‑brain barrier. It is investigated primarily as a neuro‑behavioral agent and as a tool to study peptide transport and cholinergic interactions, not as an approved therapeutic.

Mechanism of Action

Ebiratide mimics the N‑terminal ACTH(4‑9) fragment and engages central melanocortin‑related pathways without stimulating adrenal steroidogenesis. Pre‑clinical work shows the intact peptide can traverse the blood‑brain barrier and reach brain interstitial fluid, where it appears to exert activating effects that may involve cholinergic neurotransmission, as suggested by reviews linking it to cholinergic modulation. The precise receptor(s) remain undefined, but the peptide’s central activity is attributed to non‑endocrine melanocortin signaling.

What the Research Shows

Human studies have shown that intravenous, pulsatile ebiratide increases sleep onset latency, reduces slow‑wave sleep, and heightens wakefulness without altering cortisol or growth‑ hormone rhythms, indicating a specific non‑endocrine arousal effect. In a small double‑blind crossover trial with depressed and Alzheimer's patients, all doses (60‑600 µg) produced a subjective sense of increased vigor and reduced fatigue, though no cognitive improvement was observed. Animal investigations demonstrated that ebiratide crosses the blood‑brain barrier, achieving brain concentrations several‑fold higher than a non‑penetrant marker, and remains largely intact in brain interstitial fluid. Intestinal permeability studies revealed poor oral absorption, with regional differences (jejunum > ileum > duodenum > colon) and modest enhancement by certain absorption promoters. Proteolytic stability is high in intestinal fluid but reduced in mucosal homogenates, and specific protease inhibitors can improve stability. A review of nootropic agents cites ebiratide among compounds that counteract scopolamine‑induced memory deficits, implicating cholinergic mechanisms.

Reported Benefits

The available evidence suggests ebiratide can produce central activating effects, such as reduced subjective fatigue and increased alertness, in both healthy volunteers and patients with depression or Alzheimer’s disease. Its ability to cross the blood‑brain barrier and remain intact in the brain supports potential utility for probing central melanocortin or cholinergic pathways. In pre‑clinical models, it counteracts cholinergic antagonism‑induced memory disruption, indicating possible nootropic relevance.

Limitations of the Evidence

Human data are limited to small, acute trials; no long‑term efficacy or safety information exists. Cognitive or antidepressant benefits were not demonstrated, and the peptide did not improve memory in Alzheimer’s patients. Oral delivery is inefficient due to poor intestinal permeability and susceptibility to proteolysis, requiring enhancers or inhibitors that may cause membrane irritation. The exact molecular target remains unidentified, and findings are largely exploratory.

Safety Considerations

Acute intravenous administration in the reported studies was well tolerated, with no adverse events noted. However, safety conclusions are constrained by the small sample sizes and short exposure periods. Potential risks associated with absorption enhancers (e.g., membrane protein leakage) have been observed in vitro, though the enhancers tested caused less protein release than strong chelators. Comprehensive toxicity, immunogenicity, and chronic safety data are lacking.

How It Is Administered

Ebiratide has been administered intravenously in pulsatile doses (e.g., 120 µg per injection) and explored via intranasal and subcutaneous routes in research settings. Formulations are peptide solutions suitable for injection; no oral dosage forms are currently viable due to low permeability. Administration protocols are experimental and confined to controlled clinical or laboratory environments.

Routes of Administration

Goals & Uses

• NeuroprotectionNeurologyLow
• Cognitive enhancement / memory improvementNeurologicalLow
• Attention and concentration improvementCognitiveLow
• Peripheral nerve regenerationNeurologicalLow

Contraindications

• Known hypersensitivity to ACTH analoguesAllergyHigh

Adverse Effects

• Transient blood pressure changesCardiovascularRare
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• CorticosteroidsLow

Population Constraints

• Patients with adrenal tumorsOncologyRelative
• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedDeveloped by Hoechst (Germany) but did not reach marketing authorization; research compound.
• United StatesUnapprovedNever submitted for or received FDA approval; research use only.
• United KingdomUnapprovedNo MHRA approval; research use only.

Ebiratide has not received regulatory approval in any major jurisdiction. It remains a research compound studied in preclinical and early clinical settings.

Evidence & Sources

• Effects of an ACTH/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans
  Journal ArticleModerateSteiger A, et al.1991-01-01T00:00:00.000000Z
• Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients with Alzheimer's disease
  Journal ArticleModerateHeuser I, et al.1993-01-01T00:00:00.000000Z
• Effects of different absorption enhancers on the permeation of ebiratide, an ACTH analogue, across intestinal membranes
  Journal ArticleLowYamamoto A, et al.1997-01-01T00:00:00.000000Z
• Nootropic drugs and brain cholinergic mechanisms
  Journal ArticleModeratePepeu G, Spignoli G1989-01-01T00:00:00.000000Z
• Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors
  Journal ArticleLowOkagawa T, et al.1994-01-01T00:00:00.000000Z
• In-vivo blood-brain barrier transport of a novel adrenocorticotropic hormone analogue, ebiratide, demonstrated by brain microdialysis and capillary depletion methods
  Journal ArticleLowShimura T, et al.1992-01-01T00:00:00.000000Z

Frequently Asked Questions